Binnopharm Group Received 50 Marketing Authorisations Abroad in the First Ten Months of 2024
12.11.2024
During the first 10 months of 2024, Binnopharm Group, a leading pharmaceutical company, received 50 marketing authorisations for its 20 products in 11 countries: Armenia, the Republic of Belarus, Kyrgyzstan, Uzbekistan, Azerbaijan, Georgia, Moldova, Kazakhstan, Tajikistan, the Pridnestrovian Moldavian Republic, and Mongolia.
Registration procedures in accordance with the requirements of the EAEU and national requirements have been successfully completed for the following prescription and over-the-counter drug products from the Binnopharm Group portfolio: ATORVASTATIN-ALIUM (Georgia), Bisoprolol-AKOS (Armenia, Moldova, Uzbekistan, Mongolia) , VENARUS® (Moldova), DEXONAL® (Moldova), INSPIRAX® (Belarus), Clopidogrel-AKOS (Azerbaijan, Kyrgyzstan, Uzbekistan), Losartan-AKOS (Uzbekistan), Meropenem (Kazakhstan, Kyrgyzstan, Mongolia), MOXONIDINE-ALIUM (Armenia, Belarus), Neobutin® (Armenia, Belarus, Georgia), Naisulide® (Transnistria), NUROFAST® (Belarus, Kyrgyzstan, Tajikistan), NUROFAST® FORTE (Tajikistan), SULZONCEF® (Azerbaijan, Uzbekistan), Trimetazidine-AKOS MV (Azerbaijan, Uzbekistan, Belarus), Urdoxa® (Uzbekistan), Urdoxa® 500 (Armenia, Belarus, Georgia, Transnistria, Uzbekistan), Fluconazole-ALIUM (Uzbekistan), FURAGIN-ALIUM (Tajikistan, Moldova), Elmucin® (Armenia, Mongolia).
Gulnara Setdekova, Director of Research and Regulatory Affairs at Binnopharm Group: «Our goal is to become a leader in the maximum number of countries, a company that supplies modern and in-demand drug products to foreign markets. We systematically bring Binnopharm Group’s bestsellers to export countries, ensuring the necessary therapy for consumers and expanding the company’s international coverage».
Binnopharm Group products can be purchased in 14 countries around the world; the company is a leader among Russian companies that export their products to foreign countries, and also ranks first (in packaging) in the pharmaceutical market of Kyrgyzstan.
Registration procedures in accordance with the requirements of the EAEU and national requirements have been successfully completed for the following prescription and over-the-counter drug products from the Binnopharm Group portfolio: ATORVASTATIN-ALIUM (Georgia), Bisoprolol-AKOS (Armenia, Moldova, Uzbekistan, Mongolia) , VENARUS® (Moldova), DEXONAL® (Moldova), INSPIRAX® (Belarus), Clopidogrel-AKOS (Azerbaijan, Kyrgyzstan, Uzbekistan), Losartan-AKOS (Uzbekistan), Meropenem (Kazakhstan, Kyrgyzstan, Mongolia), MOXONIDINE-ALIUM (Armenia, Belarus), Neobutin® (Armenia, Belarus, Georgia), Naisulide® (Transnistria), NUROFAST® (Belarus, Kyrgyzstan, Tajikistan), NUROFAST® FORTE (Tajikistan), SULZONCEF® (Azerbaijan, Uzbekistan), Trimetazidine-AKOS MV (Azerbaijan, Uzbekistan, Belarus), Urdoxa® (Uzbekistan), Urdoxa® 500 (Armenia, Belarus, Georgia, Transnistria, Uzbekistan), Fluconazole-ALIUM (Uzbekistan), FURAGIN-ALIUM (Tajikistan, Moldova), Elmucin® (Armenia, Mongolia).
Gulnara Setdekova, Director of Research and Regulatory Affairs at Binnopharm Group: «Our goal is to become a leader in the maximum number of countries, a company that supplies modern and in-demand drug products to foreign markets. We systematically bring Binnopharm Group’s bestsellers to export countries, ensuring the necessary therapy for consumers and expanding the company’s international coverage».
Binnopharm Group products can be purchased in 14 countries around the world; the company is a leader among Russian companies that export their products to foreign countries, and also ranks first (in packaging) in the pharmaceutical market of Kyrgyzstan.
